Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.60
KERX's Cash to Debt is ranked lower than
73% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. KERX: 1.60 )
Ranked among companies with meaningful Cash to Debt only.
KERX' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 10000.00 Max: No Debt
Current: 1.6
Equity to Asset 0.22
KERX's Equity to Asset is ranked lower than
87% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. KERX: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
KERX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.83 Max: 0.93
Current: 0.22
-0.06
0.93
F-Score: 4
Z-Score: -3.39
M-Score: 3.79
WACC vs ROIC
23.27%
-606.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -551.69
KERX's Operating margin (%) is ranked lower than
72% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. KERX: -551.69 )
Ranked among companies with meaningful Operating margin (%) only.
KERX' s Operating margin (%) Range Over the Past 10 Years
Min: -15010.67  Med: -919.71 Max: 38.97
Current: -551.69
-15010.67
38.97
Net-margin (%) -705.48
KERX's Net-margin (%) is ranked lower than
75% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. KERX: -705.48 )
Ranked among companies with meaningful Net-margin (%) only.
KERX' s Net-margin (%) Range Over the Past 10 Years
Min: -13813.48  Med: -965.19 Max: 41.62
Current: -705.48
-13813.48
41.62
ROE (%) -118.98
KERX's ROE (%) is ranked lower than
85% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. KERX: -118.98 )
Ranked among companies with meaningful ROE (%) only.
KERX' s ROE (%) Range Over the Past 10 Years
Min: -246.34  Med: -108.23 Max: 68.51
Current: -118.98
-246.34
68.51
ROA (%) -66.47
KERX's ROA (%) is ranked lower than
78% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. KERX: -66.47 )
Ranked among companies with meaningful ROA (%) only.
KERX' s ROA (%) Range Over the Past 10 Years
Min: -135.67  Med: -73.82 Max: 31.09
Current: -66.47
-135.67
31.09
ROC (Joel Greenblatt) (%) -508.47
KERX's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. KERX: -508.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KERX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46369.35  Med: -6757.67 Max: 7114.49
Current: -508.47
-46369.35
7114.49
EBITDA Growth (3Y)(%) 41.40
KERX's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. KERX: 41.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KERX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.1  Med: 17.40 Max: 70.9
Current: 41.4
-45.1
70.9
EPS Growth (3Y)(%) 48.80
KERX's EPS Growth (3Y)(%) is ranked higher than
91% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. KERX: 48.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KERX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.2  Med: 17.10 Max: 60.5
Current: 48.8
-45.2
60.5
» KERX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

KERX Guru Trades in Q2 2015

Jim Simons 295,500 sh (New)
Seth Klarman 25,791,678 sh (+15.24%)
» More
Q3 2015

KERX Guru Trades in Q3 2015

Paul Tudor Jones 14,068 sh (New)
David Abrams 5,000,000 sh (New)
Seth Klarman 25,791,678 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

KERX Guru Trades in Q4 2015

Chuck Royce 341,725 sh (New)
Paul Tudor Jones 44,597 sh (+217.01%)
David Abrams 5,500,000 sh (+10.00%)
Seth Klarman 25,791,678 sh (unchged)
» More
Q1 2016

KERX Guru Trades in Q1 2016

Joel Greenblatt 25,457 sh (New)
Chuck Royce 451,725 sh (+32.19%)
David Abrams 5,719,176 sh (+3.99%)
Seth Klarman 25,791,678 sh (unchged)
Paul Tudor Jones 30,106 sh (-32.49%)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ATRA, NAS:ANIP, NAS:CERS, NAS:ADAP, NAS:CHRS, OTCPK:IPHYF, NAS:INSM, OTCPK:BIESF, NAS:ADRO, NAS:XBIT, NAS:CORT, OTCPK:GNFTF, NAS:INO, NAS:EPZM, NAS:FOLD, NAS:XNCR, NAS:MNKD, NAS:DVAX, NAS:PACB, NAS:BPMC » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc is a biopharmaceutical company focused on therapies for patients with renal disease. Its first product is the AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound.

Keryx Biopharmaceuticals Inc was incorporated in Delaware in October 1998. It is a biopharmaceutical company focused on therapies for patients with renal disease. Its product AuryxiaTM, also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound approved for the control of serum phosphorus levels in patients with CKD on dialysis.

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Klarman Gives Insight on Keryx Biopharmaceuticals Investment Guru has confidence in sole FDA-approved product
Back in November, I tried to guess Seth Klarman's (Trades, Portfolio) motives for investing in Keryx Biopharmaceuticals (NASDAQ:KERX), an unusual biotech position for the renowned value investor. In his latest letter to shareholder, the secretive guru has finally commented on this company. In November I wrote: Read more...
Seth Klarman Blames Market, Investments for Rare Down Year Klarman discusses third down year in fund's history
One of the most widely followed and profitable value investors, Seth Klarman (Trades, Portfolio) told clients that in 2015 his firm Baupost Group lost money for the third year in its history. Read more...
Seth Klarman Raises Position in Keryx Biopharmaceuticals Guru buys more than 16 million shares
Seth Klarman (Trades, Portfolio) added to his existing stake in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), a New York City-based biopharmaceutical company, with the purchase of 16,224,598 shares for a price of $3.74 per share on Oct. 14. Read more...

Ratios

vs
industry
vs
history
P/B 13.27
KERX's P/B is ranked lower than
88% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. KERX: 13.27 )
Ranked among companies with meaningful P/B only.
KERX' s P/B Range Over the Past 10 Years
Min: 1.9  Med: 6.58 Max: 70
Current: 13.27
1.9
70
P/S 33.54
KERX's P/S is ranked lower than
73% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. KERX: 33.54 )
Ranked among companies with meaningful P/S only.
KERX' s P/S Range Over the Past 10 Years
Min: 1.18  Med: 70.14 Max: 2228
Current: 33.54
1.18
2228
Current Ratio 3.14
KERX's Current Ratio is ranked lower than
62% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. KERX: 3.14 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.07 Max: 106.93
Current: 3.14
1.88
106.93
Quick Ratio 2.54
KERX's Quick Ratio is ranked lower than
65% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. KERX: 2.54 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.07 Max: 106.93
Current: 2.54
1.88
106.93
Days Inventory 1.00
KERX's Days Inventory is ranked higher than
99% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. KERX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 1365.48  Med: 2126.15 Max: 2886.82
Current: 1
1365.48
2886.82
Days Sales Outstanding 81.67
KERX's Days Sales Outstanding is ranked lower than
62% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. KERX: 81.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 1399.85
Current: 81.67
0.51
1399.85

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.21
KERX's Price/Net Current Asset Value is ranked lower than
80% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. KERX: 15.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KERX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.20 Max: 26.2
Current: 15.21
1.07
26.2
Price/Tangible Book 13.14
KERX's Price/Tangible Book is ranked lower than
83% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. KERX: 13.14 )
Ranked among companies with meaningful Price/Tangible Book only.
KERX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 6.37 Max: 25.94
Current: 13.14
0.93
25.94
Price/Median PS Value 0.45
KERX's Price/Median PS Value is ranked higher than
83% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. KERX: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
KERX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.64 Max: 69.45
Current: 0.45
0.02
69.45
Earnings Yield (Greenblatt) (%) -18.12
KERX's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. KERX: -18.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KERX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.6  Med: 176.85 Max: 27616.5
Current: -18.12
-19.6
27616.5

More Statistics

Revenue (TTM) (Mil) $19.33
EPS (TTM) $ -1.30
Beta3.08
Short Percentage of Float25.46%
52-Week Range $2.80 - 10.51
Shares Outstanding (Mil)105.82

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 40 83 174
EPS ($) -0.90 -0.08 0.63
EPS w/o NRI ($) -0.90 -0.08 0.63
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:KERX

Headlines

Articles On GuruFocus.com
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

More From Other Websites
Cramer: If the data's good, this stock could get a takeout bid Jun 27 2016
Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy Jun 27 2016
Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy Jun 27 2016
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors Jun 23 2016
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jun 21 2016
Keryx Biopharmaceuticals Appoints Two New Board Members Jun 21 2016
Keryx Biopharmaceuticals Appoints Two New Board Members Jun 21 2016
Premarket Research Report Covering the Biotech Industry Jun 15 2016
Keryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21 Jun 14 2016
Keryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21 Jun 14 2016
6 Biotechs Seriously on the Move Jun 02 2016
Here's a Reason Why Keryx (KERX) Stock Is Spiking Today Jun 02 2016
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... May 27 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : May 23, 2016 May 23 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : May 5, 2016 May 05 2016
KERYX BIOPHARMACEUTICALS INC Financials May 05 2016
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2016 By the Numbers May 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)